Home
HomeChat
Markets
AlertsCalendarScreenerCharts
Portfolio
WatchlistsPortfolioFiles
Account
Docs
Sign upJoinLog inLogin

PDS Biotechnology Corporation (PDSB) stock profile

PDS Biotechnology Corporation is a clinical-stage biopharmaceutical company focused on developing multifunctional cancer immunotherapies. Its lead product candidate, PDS0101 (HPV16), is in a Phase II clinical trial for first-line treatment of recurrent/metastatic head and neck cancer, human papillomavirus-associated malignancies, and cervical cancer. The company is also developing several preclinical product candidates, including PDS0102 (T-cell receptor gamma alternate reading frame protein for prostate and breast cancers), PDS0103 (MUC-1 for ovarian, colorectal, lung, and breast cancers), and PDS0104 (tyrosinase-related protein 2 for melanoma). Additionally, it is developing PDS0201 for tuberculosis, PDS0202 as an influenza vaccine candidate, and PDS0203 as a vaccine for COVID-19 prevention. The company has license and collaboration agreements with the National Institutes of Health, Merck Eprova AG, the U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.

Key facts

SymbolPDSB
ExchangeNASDAQ
SectorHealthcare
IndustryBiotechnology
CEOFrank K. Bedu-Addo
Employees24
HeadquartersPrinceton, NJ, US
IPO2015-09-30
Websitewww.pdsbiotech.com

Explore PDSB on Vantafin

  • PDS Biotechnology Corporation Overview
  • PDS Biotechnology Corporation Financials
  • PDS Biotechnology Corporation News
  • PDS Biotechnology Corporation Events
  • PDS Biotechnology Corporation SEC filings
  • PDS Biotechnology Corporation Insider transactions
  • PDS Biotechnology Corporation Transcripts

Frequently asked questions

What does PDS Biotechnology Corporation (PDSB) do?
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical company focused on developing multifunctional cancer immunotherapies. Its lead product candidate, PDS0101 (HPV16), is in a Phase II clinical trial for first-line treatment of recurrent/metastatic head and neck cancer, human papillomavirus-associated malignancies, and cervical cancer. The company is also developing several preclinical product candidates, including PDS0102 (T-cell receptor gamma alternate reading frame protein for prostate and breast cancers), PDS0103 (MUC-1 for ovarian, colorectal, lung, and breast cancers), and PDS0104 (tyrosinase-related protein 2 for melanoma). Additionally, it is developing PDS0201 for tuberculosis, PDS0202 as an influenza vaccine candidate, and PDS0203 as a vaccine for COVID-19 prevention. The company has license and collaboration agreements with the National Institutes of Health, Merck Eprova AG, the U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.
Where is PDSB stock listed?
PDS Biotechnology Corporation trades under the ticker PDSB on NASDAQ.
How can I research PDSB's financials and filings?
Vantafin provides PDS Biotechnology Corporation's income statement, balance sheet and cash-flow data, SEC filings, earnings-call transcripts, and insider & institutional ownership on the PDSB profile.